NTLA
Intellia Therapeutics Inc
NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY
$13.48
+8.32% today
Updated 2026-04-30
Market cap
$1.48B
P/E ratio
—
P/S ratio
21.87x
EPS (TTM)
$-3.81
Dividend yield
—
52W range
$7 – $28
Volume
5.1M
Intellia Therapeutics Inc (NTLA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $6.04M | $16.48M | $26.12M | $30.43M | $43.10M | $57.99M | $33.05M | $52.12M | $36.27M | $57.88M | $67.67M |
| Revenue growth (YoY) | — | — | +172.7% | +58.5% | +16.5% | +41.6% | +34.5% | -43.0% | +57.7% | -30.4% | +59.6% | +16.9% |
| Cost of revenue | $1.66M | $11.17M | $31.84M | $67.65M | $89.11M | $108.41M | $150.41M | $6.89M | $7.57M | $8.98M | $10.29M | $15.92M |
| Gross profit | $-1.66M | $-5.13M | $16.48M | $26.12M | $30.43M | $-65.31M | $57.99M | $33.05M | $44.55M | $27.30M | $47.59M | $51.75M |
| Gross margin | — | -84.8% | 100.0% | 100.0% | 100.0% | -151.5% | 100.0% | 100.0% | 85.5% | 75.3% | 82.2% | 76.5% |
| R&D | $10.74M | $11.17M | $31.84M | $67.65M | $89.11M | $108.41M | $150.41M | $229.81M | $419.98M | $435.07M | $466.31M | $388.86M |
| SG&A | $3.57M | $8.28M | $16.80M | $28.02M | $32.19M | $41.06M | $44.17M | $71.10M | $90.31M | $116.50M | $125.83M | $119.80M |
| Operating income | $-5.23M | $-13.41M | $-32.16M | $-69.56M | $-90.87M | $-106.37M | $-136.58M | $-267.85M | $-458.16M | $-515.29M | $-534.26M | $-440.99M |
| Operating margin | — | -221.9% | -195.2% | -266.3% | -298.6% | -246.8% | -235.5% | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| EBITDA | $-9.54M | $-13.08M | $-31.05M | $-66.56M | $-86.41M | $-100.78M | $-130.27M | $-260.96M | $-450.59M | $-506.31M | $-523.98M | $-396.77M |
| EBITDA margin | — | -216.4% | -188.5% | -254.9% | -283.9% | -233.8% | -224.6% | -789.5% | -864.5% | -1395.8% | -905.3% | -586.3% |
| EBIT | $-9.54M | $-13.41M | $-32.16M | $-69.56M | $-90.87M | $-106.37M | $-136.58M | $-267.85M | $-458.16M | $-515.29M | $-534.26M | $-412.69M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.35M | $6.89M | $8.54M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.31M | $-12.40M | $-31.63M | $-67.54M | $-85.34M | $-99.53M | $-125.57M | $-259.72M | $-474.19M | $-481.19M | $-519.02M | $-412.69M |
| Net income growth (YoY) | — | +13.4% | -155.2% | -113.5% | -26.4% | -16.6% | -26.2% | -106.8% | -82.6% | -1.5% | -7.9% | +20.5% |
| Profit margin | — | -205.1% | -192.0% | -258.6% | -280.4% | -230.9% | -216.5% | -785.8% | -909.8% | -1326.5% | -896.8% | -609.9% |